Bisphosphonates and breast carcinoma

Cancer

Volumn 80, Issue 8 SUPPL., 1997, Pages 1668-1673

  Lipton, Allan ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; ETIDRONIC ACID; PAMIDRONIC ACID; PLACEBO;

ACUTE LEUKEMIA; BONE METASTASIS; BREAST CARCINOMA; CANCER PATIENT; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; GASTROINTESTINAL TOXICITY; HUMAN; HYPERCALCEMIA; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PATHOLOGIC FRACTURE; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0030838804     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0142(19971015)80:8+<1668::aid-cncr17>3.0.co;2-y     Document Type: Conference Paper

References (33)

1. Abrams HL, Spiro R, Goldstein M. Metastases in carcinoma: analysis of 1,000 autopsied cases. Cancer 1950;3:74-6.
2. Clain A. Secondary malignant disease of bone. Br J Cancer 1965; 19:15-29.
3. Johnson AD. Pathology of metastatic tumors in bone. Clin Orthop 1970:73:8-32.
4. Galasko CSB, Bennett A. Relationship of bone destruction in skeletal metastases to osteoclasts activation and prostaglandins. Nature 1976;263:508-10.
5. Kanis JA. Bone and cancer: pathophysiology and treatment of metastases. Bone 1995;17:101S-105S.
6. Mundy GR. Bone resorption and turnover in health and disease. Bone 1987;8(Suppl 1):S9-S16.
7. Mundy GR. Identifying mechanisms for increasing bone mass. J Natl Inst Health Res 1989;1:65-8.
8. Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br J Cancer 1987;55:61-6.
9. Whitehouse JMA. Site-dependent response to chemotherapy for carcinoma of the breast. J R Soc Med 1985;78(Suppl 9):18-22.
10. Fleisch H. Bisphosphonates: mechanism of action and clinical application. J Bone Miner Res 1983;1:319-57.
11. Fleisch H. Bisphosphonates: a new class of drugs in diseases of bone and calcium metabolism. Recent Results Cancer Res 1989;116:1-28.
12. Boonecamp PM, van der Wee-Pais LJA, van Wijk-van Lennep MML, et al. Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix. J Bone Miner Res 1986;1:27-39.
13. Plasmans CMT, Kuypers W, Slooff TJJH. The effect of ethanalhydroxy-1, 1-diphosphonic acid (EHDP) on matrix induced ectopic bone formation. Clin Orthop 1978;132:233-43.
14. Altman RD, Johnston CC, Khairi MRA, et al. Influence of disodium etidronate on clinical and laboratory manifestations of Paget's disease of bone (osteitis deformans). N Engl J Med 1973;289:1379-84.
15. Storm T, Thamsborg G, Steiniche T, et al. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 1990;322:1265-71.
16. Ryzen E, Martodam R, Troxell M, et al. Intravenous etidronate in the management of malignant hypercalcaemia. Arch Intern Med 1985;145:449-52.
17. Kanis JA, Urwin GH, Gray RES, et al. Effects of intravenous etidronate on skeletal and calcium metabolism. Am J Med 1987;82:55-70.
18. Siris ES, Hyman GA, Canfield RE. Effects of dichloromethylene diphosphonate in women with breast carcinoma metastatic to the skeleton. Am J Med 1983;74:401-6.
19. Elomaa I, Blomqvist C, Grohn P, Porkka L, Kairento AL, Selander K, Lamberg-Allardt C, Holmstrum T. Long-term controlled trial of bisphosphonate in patients with osteolytic bone metastases. Lancet 1983;1:146-9.
20. Paterson AHG, Powles TJ, Kanis TA, McCloskey E, Hanson J, Ashley S. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 1993;11:59-65.
21. Coleman RE, Woll PJ, Miles M, Scrivener W, Rubens RD. Treatment of bone metastases from breast cancer with (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (APD). Br J Cancer 1988;58:621-5.
22. Morton AR, Cantrill JA, Pillai GV, McMahon A, Anderson DC, Howell A. Sclerosis of lytic bone metastases after disodium aminohydroxypropylidene bisphosphonate (APD) in patients with breast carcinoma. BMJ 1988;297:772-3.
23. Burckhardt P, Thiebaud D, Percy L, von Fliedner V. Treatment of tumor-induced osteolysis by APD. Recent Results Cancer Res 1989;116:54-66.
24. Ette JW, Bijvoet OL, Cleton FJ, van Oosterom AT, Sleeboom HP. Osteolytic bone metastases in breast carcinoma: pathogenesis, morbidity, and bisphosphonate treatment. Eur J Cancer Clin Oncol 1986;22:493-500.
25. van Holten-Verzantvoort ATM, Zwinderman AH, Aaronson NK, et al. The effect of supportive pamidronate treatment on aspects of quality of life of patients with advanced breast cancer. Eur J Cancer 1991;27:544-9.
26. van Holten-Verzantvoort ATM, Kroon HM, Bijvoet OLM, et al. Palliative pamidronate treatment in patients with bone metastases from breast cancer. J Clin Oncol 1993;11:491-8.
27. Glover D, Lipton A, Keller A, et al. Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer: a dose-seeking study. Cancer 1994;74:2949-55.
28. Hortobagyi GN, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 1996;335:1785-91.
29. Lipton A, Theriault R, Leff R, Gluck S, Stewart J, Costello S, et al. Long-term reduction of skeletal complications in breast cancer patients with osteolytic bone metastases receiving hormone therapy by monthly 90 mg pamidronate (Aredia) infusions. Proc ASCO May 1997;16: Abstract #531.
30. Demers LM, Costa L, Chinchilla V, Gaydos L, Curley E, Lipton A. Biochemical markers of bone turnover in patients with metastatic bone disease. Clin Chem 1995;41:1489-94.
31. Conte PF, Latreille J, Maurik L, Calabresi F, Santos R, Campos D, et al. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. J Clin Oncol 1996;14:2522-9.
32. Kanis JA, Powles T, Paterson AHG, McCloskey EV, Ashley S. Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone 1996;19:663-7.
33. Van Holten-Verzantvoort ATM, Hermans J, Beex LVAM, Blijham G, Cleton FJ, van Eck-Smit BCF, et al. Does supportive pamidronate treatment prevent or delay the first manifestation of bone metastases in breast cancer patients? Eur J Cancer 1996;32A:450-4.